{"Title": "Does patient education work in breast cancer? Final results from the global CARIATIDE study", "Year": 2015, "Source": "Future Oncol.", "Volume": "11", "Issue": 2, "Art.No": null, "PageStart": 205, "PageEnd": 217, "CitedBy": 11, "DOI": "10.2217/fon.14.179", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84921362283&origin=inward", "Abstract": "\u00a9 2015 Future Medicine Ltd.Aim: To determine the impact of educational materials (EMs) on the treatment compliance of postmenopausal women with hormone receptor-positive (HR+) early-stage breast cancer. Patients & methods: Patients (n = 2757) were randomized to standard aromatase inhibitors (AI) alone (group A) or with EMs (group B) in a global, real-world setting. Results: The 2-year results (n = 2242) showed EMs had no impact on compliance (82 vs 82%, group A vs B), compliance with initial AI (82 vs 81%) or persistence (90 vs 88%), confirming the 1-year interim analysis (n = 2567). Of the 2082 patients considered compliant at 1 year, 77% remained compliant at 2 years. Discontinuations (9%) were mainly attributed to AI-related side effects (68% of discontinuations). Exploratory analyses suggest a relationship between patient characteristics and compliance behaviors. Conclusion: EMs do not improve compliance in this patient population. Compliance and persistence are complex end points influenced by multiple variables. Side effects were the main reasons for discontinuations.", "AuthorKeywords": ["adherence", "anastrozole", "aromatase inhibitor", "breast cancer", "compliance", "letrozole", "persistence"], "IndexKeywords": ["Aged", "Androstadienes", "Antineoplastic Combined Chemotherapy Protocols", "Aromatase Inhibitors", "Breast Neoplasms", "Female", "Humans", "Middle Aged", "Nitriles", "Patient Compliance", "Patient Education as Topic", "Tamoxifen", "Triazoles"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 0, "EID": "2-s2.0-84921362283", "SubjectAreas": [["Oncology", "MEDI", "2730"], ["Cancer Research", "BIOC", "1306"]], "AuthorData": {"7007164817": {"Name": "Markopoulos C.", "AuthorID": "7007164817", "AffiliationID": "60067083", "AffiliationName": "Breast Unit, Athens University Medical School"}, "7005856240": {"Name": "Neven P.", "AuthorID": "7005856240", "AffiliationID": "60031069", "AffiliationName": "Breast Unit, UZ Leuven"}, "7202127762": {"Name": "Tanner M.", "AuthorID": "7202127762", "AffiliationID": "60008760", "AffiliationName": "Department of Oncology, Tampere University Hospital"}, "7101956679": {"Name": "Marty M.", "AuthorID": "7101956679", "AffiliationID": "60002900", "AffiliationName": "H\u00f4pital St Louis"}, "7101745865": {"Name": "Kreienberg R.", "AuthorID": "7101745865", "AffiliationID": "60010819", "AffiliationName": "Universit\u00e4ts-Frauenklinik"}, "7005842007": {"Name": "Atkins L.", "AuthorID": "7005842007", "AffiliationID": "60022148", "AffiliationName": "University College"}, "56072250900": {"Name": "Franquet A.", "AuthorID": "56072250900", "AffiliationID": "60006316", "AffiliationName": "International Drug Development Institute (IDDI)"}, "7006249495": {"Name": "Gnant M.", "AuthorID": "7006249495", "AffiliationID": "60011394", "AffiliationName": "Department of Surgery, Comprehensive Cancer Center, Medical University of Vienna"}, "36466863000": {"Name": "Neciosup S.", "AuthorID": "36466863000", "AffiliationID": "60071241", "AffiliationName": "Instituto Nacional de Enfermedades Neoplasicas (INEN)"}, "57195769007": {"Name": "Tesarova P.", "AuthorID": "57195769007", "AffiliationID": "60016605, 60039507", "AffiliationName": "First Faculty of Medicine and General Teaching Hospital"}, "7103186956": {"Name": "Barni S.", "AuthorID": "7103186956", "AffiliationID": "60113210", "AffiliationName": "Oncologia Medica, Azienda Ospedaliera Treviglio - Caravaggio"}, "56072090800": {"Name": "Deschamp V.", "AuthorID": "56072090800", "AffiliationID": "60004219", "AffiliationName": "AstraZeneca"}}}